Patents by Inventor Valerjans Kauss

Valerjans Kauss has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 8692021
    Abstract: Method of preparing 1-amino-1,3,3,5,5-pentamethylcyclohexane or a pharmaceutically acceptable salt thereof (Neramexane), comprising step (iv): (iv) hydrolyzing a mixture comprising an acid, 1-formamido-1,3,3,5,5-pentamethylcyclohexane and hydrogen cyanide to yield 1-amino-1,3,3,5,5-pentamethylcyclohexane.
    Type: Grant
    Filed: September 24, 2010
    Date of Patent: April 8, 2014
    Assignee: Merz Pharma GmbH & Co. KGaA
    Inventors: Markus-Rene Gold, Valerjans Kauss, Aigars Jirgensons
  • Patent number: 8288549
    Abstract: The invention relates to quinoline derivatives as well as their pharmaceutically acceptable salts. The invention further relates to a process for the preparation of such compounds. The compounds of the invention are glycine B antagonists and are therefore useful for the control and prevention of various disorders, including neurological disorders.
    Type: Grant
    Filed: September 30, 2009
    Date of Patent: October 16, 2012
    Assignee: Merz Pharma GmbH & Co. KGaA
    Inventors: Markus Henrich, Angela Bauer, Jens Nagel, Meik Sladek, Christopher Graham Raphael Parsons, Wojciech Danysz, Valerjans Kauss, Jevgenijs Rozhkovs, Igors Starchenkovs, Dina Trifanova
  • Publication number: 20120245391
    Abstract: Method of preparing 1-amino-1,3,3,5,5-pentamethylcyclohexane or a pharmaceutically acceptable salt thereof (Neramexane), comprising step (iv): (iv) hydrolyzing a mixture comprising an acid, 1-formamido-1,3,3,5,5-pentamethylcyclohexane and hydrogen cyanide to yield 1-amino-1,3,3,5,5-pentamethylcyclohexane.
    Type: Application
    Filed: September 24, 2010
    Publication date: September 27, 2012
    Applicant: MERZ PHARMA GmbH &CO. KGaA
    Inventors: Markus-Rene Gold, Valerjans Kauss, Aigars Jirgensons
  • Publication number: 20120220577
    Abstract: The invention relates to naphthalene derivatives as well as their pharmaceutically acceptable salts. The invention further relates to a process for the preparation of such compounds. The compounds of the invention are glycine B antagonists and are therefore useful for the control and prevention of various disorders, including neurological disorders.
    Type: Application
    Filed: June 4, 2010
    Publication date: August 30, 2012
    Inventors: Markus Henrich, Angela Hansen, Jens Nagel, Valerjans Kauss, Jevgenijs Rozhkovs, Ginta Grunsteine, Dina Trifanova
  • Publication number: 20120178742
    Abstract: The invention relates to heterocyclic derivatives as well as their pharmaceutically acceptable salts. The invention further relates to a process for the preparation of such compounds. The compounds of the invention are mGluR5 modulators and are therefore useful for the control and prevention of acute and/or chronic neurological disorders.
    Type: Application
    Filed: August 3, 2010
    Publication date: July 12, 2012
    Applicant: MERZ PHARMA GmbH & CO. KGaA
    Inventors: Markus Henrich, Tanja Weil, Mirko Hechenberger, Sibylle Muller, Valerjans Kauss, Ronalds Zemribo, Elina Erdmane, Gints Smits
  • Publication number: 20110212956
    Abstract: Substituted pyrazolopyrimidine derivatives of formula (I) wherein Y1, Y2, Y3, Y4 represent N or C—, whereby at least two of the groups Y1 to Y4 represent a carbon atom, R1 represents chloro or bromo, R2 to R7 represent e.g. hydrogen, methyl or ethyl; and R10 and R11 independently represent e.g. hydrogen or C1-C6alkyl, are potent mGluR5 modulators and are useful for the prevention of acute and chronic neurological disorders.
    Type: Application
    Filed: May 3, 2011
    Publication date: September 1, 2011
    Applicant: MERZ PHARMA GmbH & CO. KGaA
    Inventors: Wojciech Danysz, Andrzej Dekundy, Mirko Hechenberger, Markus Henrich, Claudia Jatzke, Jens Nagel, Christopher Graham Raphael Parsons, Tanja Weil, Juris Fotins, Aleksandrs Gutcaitas, Ivars Kalvinsh, Ronalds Zemribo, Valerjans Kauss
  • Publication number: 20110190342
    Abstract: The invention relates to quinoline derivatives as well as their pharmaceutically acceptable salts. The invention further relates to a process for the preparation of such compounds. The compounds of the invention are glycine B antagonists and are therefore useful for the control and prevention of various disorders, including neurological disorders.
    Type: Application
    Filed: September 30, 2009
    Publication date: August 4, 2011
    Inventors: Markus Henrich, Angela Bauer, Jens Nagel, Meik Sladek, Christopher Graham Raphael Parsons, Wojciech Danysz, Valerjans Kauss, Jevgenijs Rozhkovs, Igos Starchenkovs, Dina Trifanova
  • Patent number: 7985753
    Abstract: Substituted pyrazolopyrimidine derivatives of formula (I) wherein Y1, Y2, Y3, Y4 represent N or C—, whereby at least two of the groups Y1 to Y4 represent a carbon atom, R1 represents chloro or bromo, R2 to R7 represent e.g. hydrogen, methyl or ethyl; and R10 and R11 independently represent e.g. hydrogen or C1-C6alkyl, are potent mGluR5 modulators and are useful for the prevention of acute and chronic neurological disorders.
    Type: Grant
    Filed: August 3, 2007
    Date of Patent: July 26, 2011
    Assignee: MERZ PHARMA GmbH & Co. KGaA
    Inventors: Wojciech Danysz, Andrzej Dekundy, Mirko Hechenberger, Markus Henrich, Claudia Jatzke, Jens Nagel, Christopher Graham Raphael Parsons, Tanja Weil, Juris Fotins, Aleksandrs Gutcaits, Ivars Kalvinsh, Ronalds Zemribo, Valerjans Kauss
  • Patent number: 7947689
    Abstract: The invention relates to pyrazolopyrimidine derivatives of formula (I) wherein Y1, Y2 and Y3 independently are e.g. CR10, NH, S or O, whereby at least one of Y1, Y2 and Y3 represents CR10; R1 represents chloro or bromo; R2, R3, R4, R5, R6 and R7 represent e.g. hydrogen or C1-C6-alkyl, and R10 represents e.g. hydrogen, halogen or phenyl; which are potent mGluR5 modulators and are e.g. useful for the treatment of various neurological disorders.
    Type: Grant
    Filed: August 3, 2007
    Date of Patent: May 24, 2011
    Assignee: Merz Pharma GmbH & Co. KGaA
    Inventors: Wojciech Danysz, Andrzej Dekundy, Mirko Hechenberger, Markus Henrich, Claudia Jatzke, Jens Nagel, Christopher Graham Raphael Parsons, Tanja Weil, Juris Fotins, Aleksandrs Gutcaits, Ivars Kalvinsh, Ronalds Zemribo, Valerjans Kauss
  • Publication number: 20110003820
    Abstract: The invention relates to pyrazolopyrimidine derivatives as well as their pharmaceutically acceptable salts. The invention further relates to a process for the preparation of such compounds. The compounds of the invention are mGluR5 modulators and are therefore useful for the control and prevention of acute and/or chronic neurological disorders.
    Type: Application
    Filed: January 30, 2009
    Publication date: January 6, 2011
    Applicant: MERZ PHARMA GMBH & CO. KGaA
    Inventors: Markus Henrich, Tanja Weil, Sibylle Muller, Jens Nagel, Andreas Gravius, Valerjans Kauss, Ronalds Zemribo, Elina Erdmane
  • Publication number: 20100298442
    Abstract: Certain 1-aminoalkylcyclohexanes are systematically-active 5HT3 and nicotinic receptor antagonists and are useful in the inhibition of progression of or alleviation of conditions resulting from disturbances of serotoninergic or nicotinergic transmission giving them a wide range of utility in the treatment of CNS-disorders. Pharmaceutical compositions thereof for such purpose and method of making same, as well as a method-of-treating conditions which are alleviated by the employment of a 5HT3 or neuronal nicotinic receptor antagonist.
    Type: Application
    Filed: July 26, 2010
    Publication date: November 25, 2010
    Applicant: MERZ PHARMA GmbH & CO. KGaA
    Inventors: Christopher Graham Raphael Parsons, Wojciech Danysz, Markus Gold, Ivars Kalvinsh, Valerjans Kauss, Aigars Jirgensons
  • Patent number: 7598384
    Abstract: The invention relates to tetrahydroquinolinone derivatives as well as their pharmaceutically acceptable salts. The invention further relates to a process for the preparation of such compounds. The compounds of the invention are group I mGluR antagonists and are therefore useful for the control and prevention of acute and/or chronic neurological disorders.
    Type: Grant
    Filed: February 25, 2005
    Date of Patent: October 6, 2009
    Assignee: Merz Pharma GmbH & Co. KGAA
    Inventors: Aigars Jirgensons, Christopher Graham Raphael Parsons, Ieva Jaunzeme, Ivars Kalvinsh, Markus Henrich, Maksims Vanejevs, Tanja Weil, Valerjans Kauss, Wojciech Danysz
  • Publication number: 20090227582
    Abstract: The invention relates to ethynyl-substituted tetrahydroquinolinone derivatives as well as their pharmaceutically acceptable salts. The invention further relates to a process for the preparation of such compounds. The compounds of the invention are group I mGluR modulators and are therefore useful for the control and prevention of acute and/or chronic neurological disorders.
    Type: Application
    Filed: May 8, 2009
    Publication date: September 10, 2009
    Applicant: MERZ PHARMA GMBH & CO. KGAA
    Inventors: Valerjans Kauss, Ieva Jaunzeme, Aigars Jirgensons, Ivars Kalvinsh, Maksims Vanejevs, Markus Henrich, Wojciech Danysz, Claudia Jatzke, Christopher G.R. Parsons, Tanja Weil
  • Patent number: 7550482
    Abstract: The invention relates to ethynyl-substituted tetrahydroquinolinone derivatives as well as their pharmaceutically acceptable salts. The invention further relates to a process for the preparation of such compounds. The compounds of the invention are group I mGluR modulators and are therefore useful for the control and prevention of acute and/or chronic neurological disorders.
    Type: Grant
    Filed: August 24, 2005
    Date of Patent: June 23, 2009
    Assignee: Merz Pharma GmbH & Co. KGAA
    Inventors: Valerjans Kauss, Ieva Jaunzeme, Aigars Jirgensons, Ivars Kalvinsh, Maksims Vanejevs, Markus Henrich, Wojciech Danysz, Claudia Jatzke, Christopher Graham Raphael Parsons, Tanja Weil
  • Publication number: 20080039458
    Abstract: Substituted pyrazolopyrimidine derivatives of formula (I) wherein Y1, Y2, Y3, Y4 represent N or C—, whereby at least two of the groups Y1 to Y4 represent a carbon atom, R1 represents chloro or bromo, R2 to R7 represent e.g. hydrogen, methyl or ethyl; and R10 and R11 independently represent e.g. hydrogen or C1-C6alkyl, are potent mGluR5 modulators and are useful for the prevention of acute and chronic neurological disorders.
    Type: Application
    Filed: August 3, 2007
    Publication date: February 14, 2008
    Applicant: MERZ PHARMA GMBH & CO. KGAA
    Inventors: Wojciech Danysz, Andrzej Dekundy, Mirko Hechenberger, Markus Henrich, Claudia Jatzke, Jens Nagel, Christopher Parsons, Tanja Weil, Juris Fotins, Aleksandrs Gutcaits, Ivars Kalvinsh, Ronalds Zemribo, Valerjans Kauss
  • Publication number: 20080039476
    Abstract: The invention relates to pyrazolopyrimidine derivatives of formula (I) wherein Y1, Y2 and Y3 independently are e.g. CR10, NH, S or O, whereby at least one of Y1, Y2 and Y3 represents CR10; R1 represents chloro or bromo; R2, R3, R4, R5, R6 and R7 represent e.g. hydrogen or C1-C6-alkyl, and R10 represents e.g. hydrogen, halogen or phenyl; which are potent mGluR5 modulators and are e.g. useful for the treatment of various neurological disorders.
    Type: Application
    Filed: August 3, 2007
    Publication date: February 14, 2008
    Applicant: MERZ PHARMA GMBH & CO. KGAA
    Inventors: Wojciech Danysz, Andrzej Dekundy, Mirko Hechenberger, Markus Henrich, Claudia Jatzke, Jens Nagel, Christopher Graham Raphael Parsons, Tanja Weil, Juris Fotins, Aleksandrs Gutcaits, Ivars Kalvinsh, Ronalds Zemribo, Valerjans Kauss
  • Publication number: 20080032998
    Abstract: Substituted pyrazolopyrimidine derivatives of formula (I) wherein R1 represents chloro or bromo; R2, R3, R4, R5, R6 and R7 independently represent e.g. hydrogen or C1-6-alkyl; R8 represents a radical R9 or a radical R10, whereby one of the two radicals R8 represents R9 and the other radical R8 represents Ret; R9 represents e.g. a phenyl or thiophene group, and R10 represents e.g. hydrogen or methyl; are potent mGluR5 modulators and are useful for the prevention of acute and chronic neurological disorders.
    Type: Application
    Filed: August 3, 2007
    Publication date: February 7, 2008
    Applicant: MERZ PHARMA GMBH & CO. KGAA
    Inventors: Wojciech Danysz, Andrzej Dekundy, Mirko Hechenberger, Markus Henrich, Claudia Jatzke, Jens Nagel, Christopher Parsons, Tanja Weil, Juris Fotins, Aleksandrs Gutcaits, Ivars Kalvinsh, Ronalds Zemribo, Valerjans Kauss
  • Publication number: 20070299113
    Abstract: The invention relates to imidazothiazole derivatives as well as their pharmaceutically acceptable salts. The invention further relates to a process for the preparation of such compounds. The compounds of the invention are group I mGluR modulators and are therefore useful for the control and prevention of various disorders, including acute and/or chronic neurological disorders.
    Type: Application
    Filed: June 22, 2007
    Publication date: December 27, 2007
    Applicant: MERZ PHARMA GMBH & CO. KGAA
    Inventors: Ivars Kalvinsh, Larisa Kaulina, Valerjans Kauss, Ronalds Zemribo, Wojciech Danysz, Markus Henrich, Christopher Graham Raphael Parsons, Tanja Weil, Elina Erdmane
  • Publication number: 20070185151
    Abstract: Azabicyclic, azatricyclic and azaspirocyclic derivatives of aminocyclohexanes which are systemically-active as NMDA, 5HT3, and nicotinic receptor antagonists, pharmaceutical compostions comprising the same, method of preparation thereof, and method of treating CNS disorders which involve disturbances of glutamatergic, serotoninergic, and nicotinic transmission, treating immunomodulatory disorders, and antimalaria, antitrypanosomal, anti-Borna virus, anti-HSV and anti-Hepatitis C virus activity.
    Type: Application
    Filed: April 4, 2007
    Publication date: August 9, 2007
    Applicant: MERZ PHARMA GMBH & CO. KGAA
    Inventors: Christopher Parsons, Markus Henrich, Wojciech Danysz, Ivars Kalvinsh, Valerjans Kauss, Aigars Jirgensons, Markus Gold, Maksims Vanejevs
  • Patent number: 7238703
    Abstract: Azabicyclic, azatricyclic and azaspirocyclic derivatives of aminocyclohexanes which are systemically-active as NMDA, 5HT3, and nicotinic receptor antagonists, pharmaceutical compositions comprising the same, method of preparation thereof, and method of treating CNS disorders which involve disturbances of glutamatergic, serotoninergic, and nicotinic transmission, treating immunomodulatory disorders, and antimalaria, antitrypanosomal, anti-Borne virus, anti-HSV and anti-Hepatitis C virus activity.
    Type: Grant
    Filed: August 11, 2005
    Date of Patent: July 3, 2007
    Assignee: Merz Pharma GmbH & Co. KGAA
    Inventors: Christopher G. R. Parsons, Markus Henrich, Wojciech Danysz, Ivars Kalvinsh, Valerjans Kauss, Aigars Jirgensons, Markus Gold, Maksims Vanejevs